Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?

Trends in Neurosciences

Volumn 39, Issue 5, 2016, Pages 325-339

  Larochelle, Catherine ^a,b   Uphaus, Timo ^a   Prat, Alexandre ^b   Zipp, Frauke ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Conversion; Multiple sclerosis; Neurodegeneration; Progression; Secondary progressive; Senescence

Indexed keywords

CARRIER PROTEIN; GADOLINIUM; INTERFERON; NEUROTRANSMITTER; REACTIVE OXYGEN METABOLITE;

AGING; COGNITIVE DEFECT; DEMYELINATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXHAUSTION; EXPANDED DISABILITY STATUS SCALE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; IMMUNOSENESCENCE; LYMPHOCYTIC INFILTRATION; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; PRIORITY JOURNAL; RECURRENCE RISK; REMYELINIZATION; REVIEW; RISK FACTOR; T LYMPHOCYTE; BRAIN; DIAGNOSTIC IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

BRAIN; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEURONS;

EID: 84961147904     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2016.02.001     Document Type: Review

References (140)

1. Leray E., et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010, 133:1900-1913.
2. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
3. Planche V., et al. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Eur. J. Neurol. 2016, 23:282-289.
4. Tutuncu M., et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult. Scler. 2013, 19:188-198.
5. Paz Soldan M.M., et al. Relapses and disability accumulation in progressive multiple sclerosis. Neurology 2015, 84:81-88.
6. Zipp F., et al. Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?. JAMA Neurol. 2013, 70:1569-1574.
7. Scalfari A., et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010, 133:1914-1929.
8. Tremlett H., et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009, 73:1616-1623.
9. Huijbregts S.C., et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004, 63:335-339.
10. Ontaneda D., et al. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015, 14:208-223.
11. Chataway J., et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014, 383:2213-2221.
12. Sedel F., et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult. Scler. Relat. Disord. 2015, 4:159-169.
13. Palace J., et al. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurol. 2015, 14:497-505.
14. Ascherio A., et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014, 71:306-314.
15. Ramanujam R., et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol. 2015, 72:1117-1123.
16. Scalfari A., et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol. 2013, 70:214-222.
17. Vukusic S., Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J. Neurol. Sci. 2003, 206:135-137.
18. Tedeholm H., et al. The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J. Neurol. 2015, 262:1148-1163.
19. Imrell K., et al. HLA-DRB115 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J. Neuroimmunol. 2009, 210:128-130.
20. Rinker J.R., et al. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006, 67:1288-1290.
21. International Multiple Sclerosis Genetics Consortium (IMSGC), et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 2013, 45:1353-1360.
22. Zhao Y., et al. Does MRI lesion activity regress in secondary progressive multiple sclerosis?. Mult. Scler. 2010, 16:434-442.
23. Calabrese M., et al. The changing clinical course of multiple sclerosis: a matter of gray matter. Ann. Neurol. 2013, 74:76-83.
24. Fisher E., et al. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 2008, 64:255-265.
25. Fisniku L.K., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
26. Scalfari A., et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2014, 85:67-75.
27. Frischer J.M., et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann. Neurol. 2015, 78:710-721.
28. Gemechu J.M., Bentivoglio M. T cell recruitment in the brain during normal aging. Front. Cell Neurosci. 2012, 6:38.
29. Kared H., et al. T cells and their cytokines in persistent stimulation of the immune system. Curr. Opin. Immunol. 2014, 29:79-85.
30. - T cells in immune disorders. Trends Mol. Med. 2012, 18:446-453.
31. Thewissen M., et al. Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients. Ann. N. Y. Acad. Sci. 2005, 1051:255-262.
32. Thewissen M., et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin. Immunol. 2007, 123:209-218.
33. - costimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 2001, 108:1185-1194.
34. Lovett-Racke A.E., et al. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 1998, 101:725-730.
35. - T cells producing high levels of interferon-γ in peripheral blood of patients with multiple sclerosis. Mult. Scler. 2008, 14:1044-1055.
36. Scholz C., et al. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J. Immunol. 1998, 160:1532-1538.
37. - T cells into the brain of multiple sclerosis patients. J. Autoimmun. 2012, 38:10-19.
38. null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J. Immunol. 2007, 179:6514-6523.
39. Luchtman D.W., et al. IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments. Cytokine Growth Factor Rev. 2014, 25:403-413.
40. Ouyang X., et al. Potentiation of Th17 cytokines in aging process contributes to the development of colitis. Cell Immunol. 2011, 266:208-217.
41. Huang M.C., et al. Nuclear factor-kappaB-dependent reversal of aging-induced alterations in T cell cytokines. FASEB J. 2008, 22:2142-2150.
42. + regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:971-979.
43. Sun L., et al. Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells. Aging Cell 2012, 11:509-519.
44. Wertheimer A.M., et al. Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J. Immunol. 2014, 192:2143-2155.
45. Scholz J.L., et al. A comparative review of aging and B cell function in mice and humans. Curr. Opin. Immunol. 2013, 25:504-510.
46. Frischer J.M., et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
47. Netea M.G., et al. Innate immune memory: a paradigm shift in understanding host defense. Nat. Immunol. 2015, 16:675-679.
48. Fulop T., et al. From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. Biogerontology 2016, 17:147-157.
49. Mitsuhashi M., et al. Aging enhances release of exosomal cytokine mRNAs by Abeta1-42-stimulated macrophages. FASEB J. 2013, 27:5141-5150.
50. Suchy D., et al. Comparison of chosen activation markers of human monocytes/macrophages isolated from the peripheral blood of young and elderly volunteers. Pharmacol. Rep. 2014, 66:759-765.
51. Le Garff-Tavernier M., et al. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 2010, 9:527-535.
52. Deng X.H., et al. Cytokine-induced activation of glial cells in the mouse brain is enhanced at an advanced age. Neuroscience 2006, 141:645-661.
53. Lucin K.M., Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron 2009, 64:110-122.
54. von Bernhardi R., et al. Microglial cell dysregulation in brain aging and neurodegeneration. Front. Aging Neurosci. 2015, 7:124.
55. Ekdahl C.T., et al. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:13632-13637.
56. Liu Y., et al. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J. Neurosci. 2010, 30:2025-3208.
57. Lyons A., et al. CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J. Neurosci. 2007, 27:8309-8313.
58. Cribbs D.H., et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J. Neuroinflammation 2012, 9:179.
59. Lu T., et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004, 429:883-891.
60. Mahad D.H., et al. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015, 14:183-193.
61. Hametner S., et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann. Neurol. 2013, 74:848-861.
62. Fischer M.T., et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 2013, 136:1799-1815.
63. Lopez-Otin C., et al. The hallmarks of aging. Cell 2013, 153:1194-1217.
64. Campbell G.R., et al. The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult. Scler. 2014, 20:1806-1813.
65. Grammas P., et al. Cerebral microvascular endothelium and the pathogenesis of neurodegenerative diseases. Expert Rev. Mol. Med. 2011, 13:e19.
66. Stichel C.C., Luebbert H. Inflammatory processes in the aging mouse brain: participation of dendritic cells and T-cells. Neurobiol. Aging 2007, 28:1507-1521.
67. Elahy M., et al. Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun. Ageing 2015, 12:2.
68. Eilaghi A., et al. Normal-appearing white matter permeability distinguishes poor cognitive performance in processing speed and working memory. AJNR Am. J. Neuroradiol. 2013, 34:2119-2124.
69. Daams M., et al. Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis. Mult. Scler. 2015, Published online July 24, 2105. 10.1177/1352458515596598.
70. Daams M., et al. Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. Neurology 2015, 85:248-255.
71. Filippi M., et al. Assessment of system dysfunction in the brain through MRI-based connectomics. Lancet Neurol. 2013, 12:1189-1199.
72. Stam C.J. Modern network science of neurological disorders. Nat. Rev. Neurosci. 2014, 15:683-695.
73. Wu K., et al. Age-related changes in topological organization of structural brain networks in healthy individuals. Hum. Brain Mapp. 2012, 33:552-568.
74. Schoonheim M., et al. Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis. Mult. Scler. 2013, 20:1058-1065.
75. Shu N., et al. Diffusion tensor tractography reveals disrupted topological efficiency in white matter structural networks in multiple sclerosis. Cereb. Cortex 2011, 21:2565-2577.
76. Tewarie P., et al. Functional brain network analysis using minimum spanning trees in multiple sclerosis: an MEG source-space study. Neuroimage 2014, 88:308-318.
77. Loitfelder M., et al. Reorganization in cognitive networks with progression of multiple sclerosis: insights from fMRI. Neurology 2011, 76:526-533.
78. Encinas J.M., et al. Division-coupled astrocytic differentiation and age-related depletion of neural stem cells in the adult hippocampus. Cell Stem Cell 2011, 8:566-579.
79. Littlefield A.M., et al. Voluntary exercise attenuates LPS-induced reductions in neurogenesis and increases microglia expression of a proneurogenic phenotype in aged mice. J. Neuroinflammation 2015, 12:138.
80. Hasan K.M., et al. Quantification of the spatiotemporal microstructural organization of the human brain association, projection and commissural pathways across the lifespan using diffusion tensor tractography. Brain Struct. Funct. 2010, 214:361-373.
81. Westlye L.T., et al. Life-span changes of the human brain white matter: diffusion tensor imaging (DTI) and volumetry. Cereb. Cortex 2010, 20:2055-2068.
82. Vigano F., et al. Transplantation reveals regional differences in oligodendrocyte differentiation in the adult brain. Nat. Neurosci. 2013, 16:1370-1372.
83. Ruckh J.M., et al. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell 2012, 10:96-103.
84. Wolf S.A., et al. CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis. J. Immunol. 2009, 182:3979-3984.
85. Ziv Y., et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 2006, 9:268-275.
86. + T cells protect injured CNS neurons via IL-4. J. Clin. Invest. 2015, 125:2547.
87. Prins M., et al. Pathological differences between white and grey matter multiple sclerosis lesions. Ann. N. Y. Acad. Sci. 2015, 1351:99-113.
88. Sethi V., et al. A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2015, Published online August 13, 2015. 10.1136/jnnp-2015-311102.
89. Howell O.W., et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134:2755-2771.
90. Magliozzi R., et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
91. Serafini B., et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14:164-174.
92. Gardner C., et al. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 2013, 136:3596-3608.
93. Romme Christensen J., et al. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. PLoS ONE 2013, 8:e57820.
94. Peters A., et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011, 35:986-996.
95. Montalban X., et al. ECTRIMS 2015 (Barcelona): efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study. Mult. Scler. 2015, 23:780.
96. Kutzelnigg A., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
97. Lee Y., et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012, 487:443-448.
98. Funfschilling U., et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012, 485:517-521.
99. Ellwardt E., Zipp F. Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. Exp. Neurol. 2014, 262:8-17.
100. Paling D., et al. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. Brain 2013, 136:2305-2317.
101. Kiryu-Seo S., et al. Demyelination increases axonal stationary mitochondrial size and the speed of axonal mitochondrial transport. J. Neurosci. 2010, 30:6658-56666.
102. Witte M.E., et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J. Pathol. 2009, 219:193-204.
103. Campbell G.R., et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann. Neurol. 2011, 69:481-492.
104. Mahad D.J., et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132:1161-1174.
105. Demerens C., et al. Induction of myelination in the central nervous system by electrical activity. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9887-9892.
106. Gibson E.M., et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brain. Science 2014, 344:1252304.
107. Malone M., et al. Neuronal activity promotes myelination via a cAMP pathway. Glia 2014, 61:843-854.
108. Nedeljkovic U., et al. Effectiveness of rehabilitation in multiple sclerosis relapse on fatigue, self-efficacy and physical activity. Acta Neurol. Belg. 2015, Published online November 12, 2015. 10.1007/s13760-015-0563-4.
109. Craig J., et al. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J. Neurol. Neurosurg. Psychiatry 2003, 74:1225-1230.
110. Darwish H., et al. Serum 25-hydroxyvitamin D predicts cognitive performance in adults. Neuropsychiatry Dis. Treat. 2015, 11:2217-2223.
111. Grover S.A., et al. Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis. Neurology 2015, 85:1663-1669.
112. Liu J., et al. Impaired adult myelination in the prefrontal cortex of socially isolated mice. Nat. Neurosci. 2012, 15:1621-1623.
113. Makinodan M., et al. A critical period for social experience-dependent oligodendrocyte maturation and myelination. Science 2012, 337:1357-1360.
114. Mangin J.M., et al. Experience-dependent regulation of NG2 progenitors in the developing barrel cortex. Nat. Neurosci. 2012, 15:1192-1194.
115. Simon C., et al. Progenitors in the adult cerebral cortex: cell cycle properties and regulation by physiological stimuli and injury. Glia 2011, 59:869-881.
116. Yong V.W., et al. Altering the CNS microenvironment during neurodegeneration to promote remyelination. Mult. Scler. 2015, 21:68.
117. Lau L.W., et al. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann. Neurol. 2012, 72:419-432.
118. Ryan S.M., Nolan Y.M. Neuroinflammation negatively affects adult hippocampal neurogenesis and cognition: can exercise compensate?. Neurosci. Biobehav. Rev. 2015, 61:121-131.
119. Venneti S., et al. Molecular imaging of microglia/macrophages in the brain. Glia 2013, 61:10-23.
120. Rissanen E., et al. ECTRIMS 2015 (Barcelona): microglial activation correlates with disease progression in multiple sclerosis. Mult. Scler. 2015, 23(Suppl. 11):7-75.
121. Moore C.S., et al. Direct and indirect effects of immune and central nervous system-resident cells on human oligodendrocyte progenitor cell differentiation. J. Immunol. 2015, 194:761-772.
122. Gerhauser I., et al. Theiler's murine encephalomyelitis virus induced phenotype switch of microglia in vitro. J. Neuroimmunol. 2012, 252:49-55.
123. Miron V.E., et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 2013, 16:1211-1218.
124. Yu Z., et al. MSX3 switches microglia polarization and protects from inflammation-induced demyelination. J. Neurosci. 2015, 35:6350-6365.
125. Ganji S.K., et al. Measurement of regional variation of GABA in the human brain by optimized point-resolved spectroscopy at 7 T in vivo. NMR Biomed. 2014, 27:1167-1175.
126. Cawley N., et al. Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. Brain 2015, 138:2584-2595.
127. 11C]flumazenil positron emission tomography study. Ann. Neurol. 2015, 78:554-567.
128. Imitola J., et al. Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch. Neurol. 2006, 63:25-33.
129. Azevedo C.J., et al. In vivo evidence of glutamate toxicity in multiple sclerosis. Ann. Neurol. 2014, 76:269-278.
130. Baranzini S.E., et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 2010, 133:2603-2611.
131. Basso A.S., et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest. 2008, 118:1532-1543.
132. Pitt D., et al. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000, 6:67-70.
133. Kuhn S.A., et al. Microglia express GABA(B) receptors to modulate interleukin release. Mol. Cell. Neurosci. 2004, 25:312-322.
134. Chen Z., et al. Microglial displacement of inhibitory synapses provides neuroprotection in the adult brain. Nat. Commun. 2014, 5:4486.
135. Busche M.A., et al. Rescue of long-range circuit dysfunction in Alzheimer's disease models. Nat. Neurosci. 2015, 18:1623-1630.
136. Raftopoulos R., et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016, 15:259-269.
137. Aktas O., et al. ECTRIMS 2015 (Barcelona): anti-LINGO-1 monoclonal antibody BIIB033 improves optic nerve latency in acute optic neuritis: primary efficacy analysis of the RENEW study. Mult. Scler. 2015, 23(Suppl. 11):7-75.
138. Panitch H., et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004, 63:1788-1795.
139. Tintore M., et al. Brainstem lesions in clinically isolated syndromes. Neurology 2010, 75:1933-1938.
140. Renoux C., et al. The natural history of multiple sclerosis with childhood onset. Clin. Neurol. Neurosurg. 2008, 110:897-904.